Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...